While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.
Potential Future Treatments for Human Papilloma Virus (HPV)

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
While vaccines have emerged to treat a cancer caused by human papilloma virus, there is still a need for therapies to treat cancerous tissue caused by HPV. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about his company's research and that of the biotech industry in the study and treatment of HPV, a key virus in the development of cervical cancer.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Level Up Your Skills: Tailoring Management of HF
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?